- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03558867
Yksilöllinen lääketiede esidiabeteksessa ja varhaisessa tyypin 2 diabeteksessa (PREDICT)
Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk
Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.
Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently.
The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Prediabetes is common in overweight and obese individuals and, as with frank diabetes, it is a risk factor for cardiovascular disease, cognitive dysfunction, fatty liver, kidney, ophthalmic, renal and neuropathic disease, and cancer.
Effective management of dysglycemia in pre-diabetes and diabetes and prevention of diabetes in individuals at risk reduce the risk of organ damage and associated co-morbidities and improves the affected individuals' quality of life.
Metformin, an oral biguanide, is the first-line treatment of newly-diagnosed type 2 diabetes patients, and the pharmacological choice for preventing diabetes in individuals with pre-diabetes. Metformin is an ideal medication to initiate for diabetes prevention, due to its excellent safety profile (lack of hypoglycemia), neutral to marginally beneficial effect on body weight, evidence of cardio-protection, and low cost. However, clinical practice, backed by randomised clinical trials, suggests that metformin mono-therapy fails to achieve glycemic goals in 20-40% of type 2 diabetes patients and to prevent diabetes in approximately 20% of individuals with pre-diabetes.
While the mode of action of metformin is still being investigated, the liver and the gastrointestinal tract are thought to be the main targets responsible for the improvement in glycemia. An increasing body of evidence suggests that the gut microbiota play an important role in obesity, prediabetes and diabetes, and alterations in gut microbial composition have been described in individuals with type 2 diabetes and pre-diabetes. Interestingly, metformin-treated diabetes patients have a "healthier" gut microbial composition compared with treatment-naïve diabetes patients, and changes in gut microbial composition with metformin treatment has been suggested to contribute to the therapeutic effect of the medication.
Randomised, clinical study with parallel assignment and single-masking will be performed in treatment-naïve individuals with pre-diabetes or early type 2 diabetes (diagnosed in the last 6 months) aiming to compare the effect of metformin (extended release [XR]) 1500 mg/d administered with personalized diet (based on the Weizmann Institute Personalized Nutrition Project) or administered with a healthy (low fat) diet.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2010
- Garvan Institute of Medical Research
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion criteria:
- Prediabetes or early-stage type 2 diabetes according to the American Diabetes Association (2019) diagnostic criteria, with HbA1c ≤8.0% (64 mmol/mol).
- Women of childbearing potential willing to take precautions to avoid pregnancy throughout the study and for 3 months after the end of treatment.
- Willingness to provide written informed consent and willingness to participate and comply with the study.
Exclusion Criteria:
- Females planning a pregnancy during the course of the research or 3 months after completion of the research project. Females who breastfeed.
- Patients with type 1 diabetes, chronically active inflammatory disease, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders, including inflammatory bowel disease or celiac.
- Liver enzymes ALT and/or AST>3-times normal range limit.
- Abnormal renal function as measured by (eGFR<45 mL/min/1.73m^2).
- Individuals with a history of a psychological illness or condition that may interfere with the individual's ability to understand the requirements of the study.
- Normo-glycaemia.
- HbA1c>8.0%
- Cardiovascular event in the previous 6 months.
- Current or recent (within 24 months) treatment with a glucose lowering medication (i.e. GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, sulfonylurea, DPP-4 inhibitor or insulin).
- Current or recent (within 3 months) treatment with metformin.
- Treatment with an oral steroid.
- Treatment with antibiotics in the last 3 months.
- Treatment with immunosuppressive medications.
- Treatment with medications known to interact with metformin, including cimetidine, vitamin K antagonists and nifedipine.
- Substance abuse.
- Participants who had received an investigational new drug within the last 6 months.
- Participants involved in another clinical study.
- Participants who actively lose weight.
- Participants who had a bariatric surgery.
- Any reason the Investigator believes the participant is not likely to be adherent to the study treatment and protocol, including non-adherence to run-in.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Placebo Comparator: Metformin + Healthy diet
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet |
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
Muut nimet:
|
|
Active Comparator: Metformin + Personalized diet
Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015) |
Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Mean change in glycated haemoglobin (HbA1C, %) from baseline
Aikaikkuna: 6 months
|
Difference in the reduction of HbA1C between the groups |
6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)
Aikaikkuna: 6 months
|
Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups |
6 months
|
|
Glycaemic variability
Aikaikkuna: 6 months
|
Difference in the glycaemic variability as derived from CGM between the groups |
6 months
|
|
Body weight
Aikaikkuna: 6 months
|
Difference in the magnitude of weight loss between the groups |
6 months
|
|
Body fat mass
Aikaikkuna: 6 months
|
Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups |
6 months
|
|
Abdominal visceral fat volume
Aikaikkuna: 6 months
|
Difference in the abdominal visceral fat volume as assessed using DXA between the groups |
6 months
|
|
Serum low-density lipoprotein (LDL)-cholesterol concentration
Aikaikkuna: 6 months
|
Difference in serum LDL-cholesterol between the groups |
6 months
|
|
Serum high-density lipoprotein (HDL)-cholesterol concentration
Aikaikkuna: 6 months
|
Difference in serum HDL-cholesterol concentration between the groups |
6 months
|
|
Serum triglycerides concentration
Aikaikkuna: 6 months
|
Difference in serum triglycerides between the groups |
6 months
|
|
Blood pressure
Aikaikkuna: 6 months
|
Difference in diastolic and systolic blood pressure between the groups |
6 months
|
|
Liver fat
Aikaikkuna: 6 months
|
Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups |
6 months
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Gut microbiome (exploratory)
Aikaikkuna: 6 months
|
Difference in gut microbiome features between the groups |
6 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Dorit Samocha-Bonet, PhD, Garvan Institute of Medical Research
- Päätutkija: Jerry Greenfield, MD, PhD, Garvan Institute of Medical Research
- Päätutkija: Eran Elinav, MD, PhD, Weizmann Institute of Science
- Päätutkija: Eran Segal, PhD, Weizmann Institute of Science
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Endokriinisen järjestelmän sairaudet
- Metaboliset sairaudet
- Glukoosiaineenvaihduntahäiriöt
- Diabetes mellitus
- Hyperinsulinismi
- Hyperglykemia
- Ravitsemukselliset ja aineenvaihduntataudit
- Diabetes mellitus, tyyppi 2
- Insuliiniresistenssi
- Glukoosi-intoleranssi
- Orgaaniset kemikaalit
- Terapeuttiset lääkkeet
- Ruokavalio, ruoka ja ravitsemus
- Fysiologiset ilmiöt
- Ravitsemusfysiologiset ilmiöt
- Ruokavaliohoito
- Ravitsemusterapia
- Biguanides
- Guanidiinit
- Amidiinit
- Metformiini
- Ruokavalio
- Ruokavalio, terveellinen
- Ruokavalio, rasvarajoitettu
Muut tutkimustunnusnumerot
- SVH 17/080
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .